Skip to main content
Clinical Trials/ISRCTN15320064
ISRCTN15320064
Active, not recruiting
Phase 3

Comparing the effectiveness of test and treat approaches with doxycycline or the triple-drug therapy with ivermectin/diethylcarbamazine/albendazole vs ivermectin/albendazole for targeted elimination of lymphatic filariasis in a Phase III clinical trial

Kumasi Centre for Collaborative Research in Tropical Medicine0 sites480 target enrollmentMarch 29, 2022

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Kumasi Centre for Collaborative Research in Tropical Medicine
Enrollment
480
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 29, 2022
End Date
January 31, 2026
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \=5 years
  • 2\. LF\-infected person (CFA positive)
  • 3\. Able and willing to give informed consent

Exclusion Criteria

  • Specific exclusion criteria for DOX 100 participants:
  • 1\. Age \<14 years or \>70 years
  • 2\. Body weight \<40 kg
  • 3\. Pregnant or breastfeeding women
  • 4\. Women of childbearing potential not using an agreed method of contraception (including abstinence; oral contraceptives are not allowed because of interaction with trial drugs)
  • 5\. Known hepatic or renal dysfunction or disease of the central nervous system (CNS)
  • 6\. History of alcohol or drug abuse
  • 7\. History of serious adverse reactions to doxycycline or other tetracyclines
  • 8\. History of photosensitivity reactions after taking drugs.
  • 9\. Concomitant medication with antacids containing aluminium, magnesium or sucralfate and not able to discontinue

Outcomes

Primary Outcomes

Not specified

Similar Trials